Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

JHOP - February 2023 Vol 13, No 1

Case Reports

Original Article

Practical Issues in Pharmacy Management

FDA Oncology Update

Perspective

Case Reports

A Pregnant 19-Year-Old Patient with Refractory Immune Thrombocytopenia and Concomitant SARS-CoV-2 Infection: Case Report

Rebecca Rezac, PharmD, and Jaimie Wittig, PharmD, BCOP

Anakinra Used in a Patient with Diffuse Large B-Cell Lymphoma and Steroid-Refractory Immune Effector Cell–Associated Neurotoxicity Syndrome: Case Report

Drew A. Wells, PharmD, BCPS; Kori Holman, PharmD, BCOP; Brion Randolph, MD; Dennis Marjoncu, PharmD, BCOP

Original Article

Comparing the Efficacy and Safety of Reference Drug Filgrastim and Biosimilar Filgrastim-sndz in Pediatric Patients Used for Post–Hematopoietic Stem-Cell Transplant Engraftment or Chemotherapy-Induced Febrile Neutropenia Prophylaxis

Cassandra Rush, PharmD; Ashley Sabus, PharmD, BCOP; Obehi Enabulele, PharmD, MBA, MS; Abby Kim, BA, PharmD, BCOP

Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego

Mina Nikanjam, MD, PhD; Jose Tinajero, PharmD; Mary McGann, PharmD, BCOP; Jerry Li, PharmD; Jincheng Yang, PharmD; Felicity Shen, PharmD; Jason K. Sicklick, MD; Shumei Kato, MD; Edmund Capparelli, PharmD; Razelle Kurzrock, MD

Economic Burden of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the First Year After Initiating Treatment with a Novel Agent

Elisabetta Malangone-Monaco, DrPH; Kellie Ryan, MPH; Elizabeth H. Marchlewicz, PhD, MPH, RD; Joyce Lo, PharmD; Scott Huntington, MD, MPH

Practical Issues in Pharmacy Management

Cost-Savings Using Patients’ Own Medication Supply of Letermovir for Allogeneic Hematopoietic Stem-Cell Transplant Recipients During Hospitalization

Harrison S. Yoon, PharmD; Mallory Crain, PharmD, BCOP; Marissa Olson, PharmD, BCOP; Anupam Pande, MD, MPH; Jeff O. Klaus, PharmD, BCPS

FDA Oncology Update

Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation

Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma

FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma

Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer

Krazati Received Accelerated FDA Approval for NSCLC with KRAS G12C Mutation

Online Only